up-to-date with a click!
Update September, 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications September 2017

Other

  1. Pokharel Y, Sharma PP, Qintar M et al. High-sensitivity C-reactive protein levels and health status outcomes after myocardial infarction. Atherosclerosis 2017; 266:16-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=28946036
  2. Williams BR, Amos Bailey F, Kvale E et al. Continuation of non-essential medications in actively dying hospitalised patients. BMJ supportive & palliative care 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28904011
  3. Hayward RA. When to Start a Statin Is a Preference-Sensitive Decision. Circulation 2017; 136:1099-1101. http://www.ncbi.nlm.nih.gov/pubmed/?term=28923904
  4. Kim DW, Kim HK, Bae EK. The effects of lifestyle modification and statin therapy on the circulatory markers for vascular risk in patients with epilepsy. Epilepsy & behavior : E&B 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28927716
  5. Showande SJ, Adegbolagun OM, Igbinoba SI, Fakeye TO. In vivo pharmacodynamic and pharmacokinetic interactions of Hibiscus sabdariffa calyces extracts with simvastatin. Journal of clinical pharmacy and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28925046
  6. Lee JS, Gonzales R, Vittinghoff E et al. Appropriate Reconciliation of Cardiovascular Medications After Elective Surgery and Postdischarge Acute Hospital and Ambulatory Visits. Journal of hospital medicine 2017; 12:723-730. http://www.ncbi.nlm.nih.gov/pubmed/?term=28914276
  7. Radermecker RP. [Lipertance(R) The ASCOT single-pill combination has finally arrived]. Revue medicale de Liege 2017; 72:416-422. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892318

Add on treatments

  1. Guimaraes ES, Cerda A, Dorea EL et al. Effects of short term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940978
  2. Hayward RA. When to Start a Statin Is a Preference-Sensitive Decision. Circulation 2017; 136:1099-1101. http://www.ncbi.nlm.nih.gov/pubmed/?term=28923904
  3. Bartlett LE, Pratt N, Roughead EE. Does a fixed dose combination of amlodipine and atorvastatin improve persistence to therapy in the Australian population? Current medical research and opinion 2017:1-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28945105
  4. Leiter LA, Cariou B, Muller-Wieland D et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28905478
  5. Bove M, Fogacci F, Cicero A. Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opin Drug Metab Toxicol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28922021
  6. Lin XL, Liu MH. Statin and ezetimibe combination therapy: New therapeutic options for lowering Low-Density Lipoprotein Cholesterol. Int J Cardiol 2017; 247:49. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916087
  7. Superko HR, Zhao XQ, Hodis HN, Guyton JR. Niacin and heart disease prevention: Engraving its tombstone is a mistake. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28927896
  8. Koopal C, Marais AD, Westerink J et al. Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized, placebo-controlled, crossover trial. Journal of lipid research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28928170
  9. Carris NW, Tipparaju SM, Magness DJ et al. Pleiotropic effects of metformin to rescue statin-induced muscle injury and insulin resistance: A proposed mechanism and potential clinical implications. Medical hypotheses 2017; 107:39-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=28915960
  10. Nasoohi S, Simani L, Khodagholi F et al. Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin. Nutritional neuroscience 2017:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28946820
  11. Cicero AFG, Colletti A, Bajraktari G et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition reviews 2017; 75:731-767. http://www.ncbi.nlm.nih.gov/pubmed/?term=28938795
  12. Nurullahoglu-Atalik KE, Kutlu S, Solak H, Koca RO. Cilostazol enhances atorvastatin-induced vasodilation of female rat aorta during aging. Physiology international 2017; 104:226-234. http://www.ncbi.nlm.nih.gov/pubmed/?term=28956637
  13. Freitas Gouveia M, Trueb RM. Unsuccessful Treatment of Alopecia Areata with Simvastatin/Ezetimibe: Experience in 12 Patients. Skin appendage disorders 2017; 3:156-160. http://www.ncbi.nlm.nih.gov/pubmed/?term=28879192
  14. Wan Q, Li L, Yang S, Chu F. Impact of Statins on Arteriovenous Fistulas Outcomes: A Meta-Analysis. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28960860
  15. Kato Y, Mukai Y, Rane A et al. Combined effect of telmisartan and fluvastatin on arachidonic acid metabolism in human liver microsomes. Xenobiotica 2017:1-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=28933256

Adherence

  1. Al Hamarneh YN, Tsuyuki RT, Jones CA et al. Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled RxEACH Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28912054
  2. Bravata DM, Myers LJ, Cheng E et al. Development and Validation of Electronic Quality Measures to Assess Care for Patients With Transient Ischemic Attack and Minor Ischemic Stroke. Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28912200
  3. Khan NA, McAlister FA, Pilote L et al. Secondary prevention treatment after acute stroke in older South Asian, Chinese and other Canadians: a retrospective data analysis. CMAJ open 2017; 5:E702-e709. http://www.ncbi.nlm.nih.gov/pubmed/?term=28899946
  4. Pichardo-Almarza C, Diaz-Zuccarini V. Understanding the Effect of Statins and Patient Adherence in Atherosclerosis via a Quantitative Systems Pharmacology Model Using a Novel, Hybrid, and Multi-Scale Approach. Frontiers in pharmacology 2017; 8:635. http://www.ncbi.nlm.nih.gov/pubmed/?term=28955237
  5. Janjic M, Pappa F, Karagkiozaki V et al. Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning. International journal of nanomedicine 2017; 12:6343-6355. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919738
  6. Ofori-Asenso R, Jakhu A, Zomer E et al. Adherence and Persistence among Statin Users aged 65 years and over: A Systematic Review and Meta-analysis. J Gerontol A Biol Sci Med Sci 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28958039
  7. Kim J, Lee HS, Nam CM, Heo JH. Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916672

Atherosclerosis & Imaging

  1. Kim SM, Ko HK, Noh M et al. Factors Affecting Patency Following Successful Percutaneous Intervention for Dysfunctional Hemodialysis Vascular Access. Annals of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28887254
  2. Honda S, Sidharta SL, Shishikura D et al. High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy. Atherosclerosis 2017; 265:110-116. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881268
  3. Miyoshi T, Kohno K, Asonuma H et al. Effect of Intensive and Standard Pitavastatin Treatment With or Without Eicosapentaenoic Acid on Progression of Coronary Artery Calcification Over 12 Months- Prospective Multicenter Study. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28867681
  4. Nicholls SJ, Puri R. Implications of GLAGOV study. Curr Opin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28937411
  5. Cariou B, Guerin P, Le May C et al. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study. Diabetes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28865748
  6. Janjic M, Pappa F, Karagkiozaki V et al. Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning. International journal of nanomedicine 2017; 12:6343-6355. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919738
  7. Carmo M, Barbetta I, Bissacco D et al. Development and validation of a score to predict life expectancy after carotid endarterectomy in asymptomatic patients. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943008
  8. Min JK, Chandrashekhar Y, Narula J. The Immediate Effects of Statins on Coronary Atherosclerosis: Can Phenotype Explain Outcome? JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28917681
  9. Soden PA, Zettervall SL, Deery SE et al. Black patients present with more severe vascular disease and a greater burden of risk factors than white patients at time of major vascular intervention. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28951156
  10. Min JK, Chandrashekhar Y, Narula J. The Immediate Effects of Statins on Coronary Atherosclerosis: Can Phenotype Explain Outcome? JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28917681
  11. Nishiguchi T, Kubo T, Tanimoto T et al. Effect of Early Pitavastatin Therapy on Coronary Fibrous-Cap Thickness Assessed by Optical Coherence Tomography in Patients With Acute Coronary Syndrome: The ESCORT Study. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28917689
  12. Lee DH, Youn HJ, Jung HO et al. Coronary artery calcium score plays an important role for cardiovascular risk stratification in the statin benefit groups of asymptomatic individuals. Lipids Health Dis 2017; 16:172. http://www.ncbi.nlm.nih.gov/pubmed/?term=28899385

Atorvastatin/Rosuvastatin

  1. Kim MH, Kim CE, Kim SW. Rosuvastatin inhibits high glucose-stimulated upregulation of VCAM-1 via the MAPK-signalling pathway in endothelial cells. Acta Cardiol 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28885098
  2. Gao X, Nan Y, Zhao Y et al. Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5. Biochim Biophys Acta 2017; 1862:1512-1519. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919478
  3. Jung KY, Kim KM, Han SK et al. Effect of Rosuvastatin on Cholesterol Efflux Capacity and Endothelial Function in Type 2 Diabetes Mellitus and Dyslipidemia. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943594
  4. Beg S, Katare OP, Singh B. Formulation by design approach for development of ultrafine self-nanoemulsifying systems of rosuvastatin calcium containing long-chain lipophiles for hyperlipidemia management. Colloids and surfaces. B, Biointerfaces 2017; 159:869-879. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892871
  5. Al-Habsi AA, Massarsky A, Moon TW. Atorvastatin alters gene expression and cholesterol synthesis in primary rainbow trout (Oncorhynchus mykiss) hepatocytes. Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919473
  6. Bartlett LE, Pratt N, Roughead EE. Does a fixed dose combination of amlodipine and atorvastatin improve persistence to therapy in the Australian population? Current medical research and opinion 2017:1-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28945105
  7. Li YR, Tsai SS, Lin YS et al. Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction. Diabetology & metabolic syndrome 2017; 9:71. http://www.ncbi.nlm.nih.gov/pubmed/?term=28932290
  8. Zhong P, Wu D, Ye X et al. Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis. Drug design, development and therapy 2017; 11:2517-2526. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919704
  9. Gabr MM, Mortada SM, Sallam MA. Carboxylate cross-linked cyclodextrin: A nanoporous scaffold for enhancement of rosuvastatin oral bioavailability. Eur J Pharm Sci 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28931488
  10. Li YH, Wang LH, Li Q et al. Effects of rosuvastatin on pentraxin 3 level and platelet aggregation rate in elderly patients with acute myocardial infarction undergoing elective interventional therapy: a double-blind controlled study. Eur Rev Med Pharmacol Sci 2017; 21:3730-3735. http://www.ncbi.nlm.nih.gov/pubmed/?term=28925467
  11. Liu GL, Lei R, Duan SB et al. Atorvastatin alleviates iodinated contrast media-induced cytotoxicity in human proximal renal tubular epithelial cells. Experimental and therapeutic medicine 2017; 14:3309-3313. http://www.ncbi.nlm.nih.gov/pubmed/?term=28912882
  12. Leite GAA, Figueiredo TM, Pacheco TL et al. Vitamin C partially prevents reproductive damage in adult male rats exposed to rosuvastatin during prepuberty. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28887090
  13. Janjic M, Pappa F, Karagkiozaki V et al. Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning. International journal of nanomedicine 2017; 12:6343-6355. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919738
  14. Indumathi C, Anusha N, Vinod KV et al. Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils. J Clin Diagn Res 2017; 11:Fc01-fc05. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892923
  15. Lau TW, Tan KE, Choo JC et al. Regional Evidence and International Recommendations to Guide Lipid Management in Asian Patients with Type 2 Diabetes with Special Reference to Renal Dysfunction. Journal of diabetes 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28960806
  16. Zhang N, Song C, Zhao B et al. Neovascularization and Synaptic Function Regulation with Memantine and Rosuvastatin in a Rat Model of Chronic Cerebral Hypoperfusion. Journal of molecular neuroscience : MN 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28920182
  17. Guirao V, Marti-Sistac O, DeGregorio-Rocasolano N et al. Specific rescue by ortho-hydroxy atorvastatin of cortical GABAergic neurons from previous oxygen/glucose deprivation: role of pCREB. Journal of neurochemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881028
  18. Lee DH, Youn HJ, Jung HO et al. Coronary artery calcium score plays an important role for cardiovascular risk stratification in the statin benefit groups of asymptomatic individuals. Lipids Health Dis 2017; 16:172. http://www.ncbi.nlm.nih.gov/pubmed/?term=28899385
  19. Kanno M, Nakayama M, Zhu WJ et al. Rosuvastatin pretreatment suppresses distant organ injury following unilateral renal ischemia-reperfusion in hypertensive Dahl salt-sensitive rats. Nephrology (Carlton) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940950
  20. Nasoohi S, Simani L, Khodagholi F et al. Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin. Nutritional neuroscience 2017:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28946820
  21. Irwin JC, Khalesi S, Fenning AS, Vella RK. The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: A systematic review and meta-analysis. Pharmacol Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943224
  22. Nurullahoglu-Atalik KE, Kutlu S, Solak H, Koca RO. Cilostazol enhances atorvastatin-induced vasodilation of female rat aorta during aging. Physiology international 2017; 104:226-234. http://www.ncbi.nlm.nih.gov/pubmed/?term=28956637
  23. Radermecker RP. [Lipertance(R) The ASCOT single-pill combination has finally arrived]. Revue medicale de Liege 2017; 72:416-422. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892318
  24. Urbano F, Bugliani M, Filippello A et al. Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat beta-Cells. Direct Effect of Oxidative Stress. Scientific reports 2017; 7:11863. http://www.ncbi.nlm.nih.gov/pubmed/?term=28928397
  25. Kim J, Lee HS, Nam CM, Heo JH. Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916672

Basic science

  1. Kim MH, Kim CE, Kim SW. Rosuvastatin inhibits high glucose-stimulated upregulation of VCAM-1 via the MAPK-signalling pathway in endothelial cells. Acta Cardiol 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28885098
  2. Zaid AN, Shtayah R, Qadumi A et al. Stability of extemporaneously prepared rosuvastatin oral suspension. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2017; 74:1579-1583. http://www.ncbi.nlm.nih.gov/pubmed/?term=28947528
  3. Marques Dos Santos CH, Dourado DM, Kato da Silva BA et al. Atorvastatin Protect Kidney From Remote Reperfusion Injury. Annals of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28887239
  4. Zhou Q, Luo A, Kummerow FA. Lovastatin reversed the enhanced sphingomyelin caused by 27-hydroxycholesterol in cultured vascular endothelial cells. Biochemistry and biophysics reports 2016; 5:127-133. http://www.ncbi.nlm.nih.gov/pubmed/?term=28955814
  5. Simakova MN, Bisen S, Dopico AM, Bukiya AN. Statin therapy exacerbates alcohol-induced constriction of cerebral arteries via modulation of ethanol-induced BK channel inhibition in vascular smooth muscle. Biochem Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28865873
  6. Gao X, Nan Y, Zhao Y et al. Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5. Biochim Biophys Acta 2017; 1862:1512-1519. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919478
  7. Zandl-Lang M, Fanaee-Danesh E, Sun Y et al. Regulatory effects of simvastatin and apoJ on APP processing and amyloid-beta clearance in blood-brain barrier endothelial cells. Biochim Biophys Acta 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28941799
  8. Ungaro F, Catanzano O, d'Angelo I et al. Microparticle-embedded fibroin/alginate beads for prolonged local release of simvastatin hydroxyacid to mesenchymal stem cells. Carbohydrate polymers 2017; 175:645-653. http://www.ncbi.nlm.nih.gov/pubmed/?term=28917913
  9. Bhuyan AAM, Nussle S, Cao H et al. Simvastatin, a Novel Stimulator of Eryptosis, the Suicidal Erythrocyte Death. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2017; 43:492-506. http://www.ncbi.nlm.nih.gov/pubmed/?term=28930754
  10. Al-Habsi AA, Massarsky A, Moon TW. Atorvastatin alters gene expression and cholesterol synthesis in primary rainbow trout (Oncorhynchus mykiss) hepatocytes. Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919473
  11. Gabr MM, Mortada SM, Sallam MA. Carboxylate cross-linked cyclodextrin: A nanoporous scaffold for enhancement of rosuvastatin oral bioavailability. Eur J Pharm Sci 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28931488
  12. Liu GL, Lei R, Duan SB et al. Atorvastatin alleviates iodinated contrast media-induced cytotoxicity in human proximal renal tubular epithelial cells. Experimental and therapeutic medicine 2017; 14:3309-3313. http://www.ncbi.nlm.nih.gov/pubmed/?term=28912882
  13. Leite GAA, Figueiredo TM, Pacheco TL et al. Vitamin C partially prevents reproductive damage in adult male rats exposed to rosuvastatin during prepuberty. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28887090
  14. Vieira G, Cavalli J, Goncalves ECD et al. Effects of Simvastatin Beyond Dyslipidemia: Exploring Its Antinociceptive Action in an Animal Model of Complex Regional Pain Syndrome-Type I. Frontiers in pharmacology 2017; 8:584. http://www.ncbi.nlm.nih.gov/pubmed/?term=28928655
  15. Tricarico PM, Gratton R, Braga L et al. 25-Hydroxycholesterol and inflammation in Lovastatin-deregulated mevalonate pathway. The international journal of biochemistry & cell biology 2017; 92:26-33. http://www.ncbi.nlm.nih.gov/pubmed/?term=28918367
  16. Bleda S, de Haro J, Acin F. Statin potential Nlrp1 inflammasome gene expression modulation via Srebp-1 pathway in peripheral arterial disease. Int J Cardiol 2017; 247:12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916052
  17. Yu SY, Dong B, Tang L, Zhou SH. Statin regulates NLRP1 inflammasome expression through SREBP1: A novel anti-atherosclerotic mechanism. Int J Cardiol 2017; 247:11. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916051
  18. Karlic H, Haider F, Thaler R et al. Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines. Int J Mol Sci 2017; 18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28914765
  19. Janjic M, Pappa F, Karagkiozaki V et al. Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning. International journal of nanomedicine 2017; 12:6343-6355. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919738
  20. Tse DY, Kim SJ, Chung I et al. The ocular toxicity and pharmacokinetics of simvastatin following intravitreal injection in mice. International journal of ophthalmology 2017; 10:1361-1369. http://www.ncbi.nlm.nih.gov/pubmed/?term=28944193
  21. Zanoni C, Aiello G, Arnoldi A, Lammi C. Hempseed Peptides Exert Hypocholesterolemic Effects with a Statin-Like Mechanism. Journal of agricultural and food chemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28931275
  22. Heringer de Souza F, Todeschini V, Sangoi MDS. Chemometric-Assisted Spectrophotometric Method for the Simultaneous Quantitative Determination of Ezetimibe and Simvastatin in Their Combined Dosage Forms. J AOAC Int 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28877782
  23. Maslanka A, Stolarczyk M, Apola A et al. Simultaneous Determination of Acetylsalicylic Acid, Hydrochlorothiazide, Enalapril, and Atorvastatin in a Polypill-Based Quaternary Mixture by TLC. J AOAC Int 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28882196
  24. Swerts AA, Santos BFE, Bruzadelli SR et al. Treatment of experimental periodontal disease by laser therapy in simvastatin-modified rats. Journal of applied oral science : revista FOB 2017; 25:387-395. http://www.ncbi.nlm.nih.gov/pubmed/?term=28877277
  25. Dikshit R, Tallapragada P. Statistical optimization of lovastatin and confirmation of nonexistence of citrinin under solid-state fermentation by Monascus sanguineus. Journal of food and drug analysis 2016; 24:433-440. http://www.ncbi.nlm.nih.gov/pubmed/?term=28911599
  26. Zhang N, Song C, Zhao B et al. Neovascularization and Synaptic Function Regulation with Memantine and Rosuvastatin in a Rat Model of Chronic Cerebral Hypoperfusion. Journal of molecular neuroscience : MN 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28920182
  27. Guirao V, Marti-Sistac O, DeGregorio-Rocasolano N et al. Specific rescue by ortho-hydroxy atorvastatin of cortical GABAergic neurons from previous oxygen/glucose deprivation: role of pCREB. Journal of neurochemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881028
  28. Magan-Fernandez A, Fernandez-Barbero JE, F OV et al. Simvastatin exerts antiproliferative and differentiating effects on MG63 osteoblast-like cells: Morphological and immunocytochemical study. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28868611
  29. Kanno M, Nakayama M, Zhu WJ et al. Rosuvastatin pretreatment suppresses distant organ injury following unilateral renal ischemia-reperfusion in hypertensive Dahl salt-sensitive rats. Nephrology (Carlton) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940950
  30. Nasoohi S, Simani L, Khodagholi F et al. Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin. Nutritional neuroscience 2017:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28946820
  31. Villarino N, Signaevskaia L, van Niekerk J et al. A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. Oncotarget 2017; 8:53154-53167. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881801
  32. Nurullahoglu-Atalik KE, Kutlu S, Solak H, Koca RO. Cilostazol enhances atorvastatin-induced vasodilation of female rat aorta during aging. Physiology international 2017; 104:226-234. http://www.ncbi.nlm.nih.gov/pubmed/?term=28956637
  33. Kang M, Lee KH, Lee HS et al. Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB/LIN28/let-7 miRNA signaling pathway. PLoS One 2017; 12:e0184644. http://www.ncbi.nlm.nih.gov/pubmed/?term=28910332
  34. Zhao SP, Li R, Dai W et al. Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARalpha signaling pathway. PLoS One 2017; 12:e0184949. http://www.ncbi.nlm.nih.gov/pubmed/?term=28934253
  35. Urbano F, Bugliani M, Filippello A et al. Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat beta-Cells. Direct Effect of Oxidative Stress. Scientific reports 2017; 7:11863. http://www.ncbi.nlm.nih.gov/pubmed/?term=28928397
  36. Karagkounis G, DeVecchio J, Ferrandon S, Kalady MF. Simvastatin enhances radiation sensitivity of colorectal cancer cells. Surgical endoscopy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916945
  37. Leone G, Consumi M, Pepi S et al. Alginate-gelatin formulation to modify lovastatin release profile from red yeast rice for hypercholesterolemia therapy. Therapeutic delivery 2017; 8:843-854. http://www.ncbi.nlm.nih.gov/pubmed/?term=28944737
  38. Atilano-Roque A, Joy MS. Characterization of simvastatin acid uptake by organic anion transporting polypeptide 3A1 (OATP3A1) and influence of drug-drug interaction. Toxicology in vitro : an international journal published in association with BIBRA 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28887287
  39. Zhao W, Li J, He X et al. In vitro steatosis hepatic cell model to compare the lipid-lowering effects of pomegranate peel polyphenols with several other plant polyphenols as well as its related cholesterol efflux mechanisms. Toxicology reports 2014; 1:945-954. http://www.ncbi.nlm.nih.gov/pubmed/?term=28962306
  40. Kato Y, Mukai Y, Rane A et al. Combined effect of telmisartan and fluvastatin on arachidonic acid metabolism in human liver microsomes. Xenobiotica 2017:1-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=28933256
  41. Guo JE, Mi SB, Yan XC et al. [Effects of Gualou Xiebai Banxia decoction on blood lipid content, oxidative stress and ox-LDL/Lox-1 pathway in ApoE-/- mice]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 2017; 42:752-757. http://www.ncbi.nlm.nih.gov/pubmed/?term=28959848

Cancer

  1. Islam MM, Yang HC, Nguyen PA et al. Exploring association between statin use and breast cancer risk: an updated meta-analysis. Archives of gynecology and obstetrics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940025
  2. Joo MK, Park JJ, Chun HJ. Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors. Dig Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881340
  3. Karlic H, Haider F, Thaler R et al. Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines. Int J Mol Sci 2017; 18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28914765
  4. Magan-Fernandez A, Fernandez-Barbero JE, F OV et al. Simvastatin exerts antiproliferative and differentiating effects on MG63 osteoblast-like cells: Morphological and immunocytochemical study. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28868611
  5. Villarino N, Signaevskaia L, van Niekerk J et al. A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. Oncotarget 2017; 8:53154-53167. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881801
  6. Kang M, Lee KH, Lee HS et al. Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB/LIN28/let-7 miRNA signaling pathway. PLoS One 2017; 12:e0184644. http://www.ncbi.nlm.nih.gov/pubmed/?term=28910332
  7. Karagkounis G, DeVecchio J, Ferrandon S, Kalady MF. Simvastatin enhances radiation sensitivity of colorectal cancer cells. Surgical endoscopy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916945

Children

  1. Islam MM, Yang HC, Nguyen PA et al. Exploring association between statin use and breast cancer risk: an updated meta-analysis. Archives of gynecology and obstetrics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940025
  2. Joo MK, Park JJ, Chun HJ. Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors. Dig Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881340
  3. Karlic H, Haider F, Thaler R et al. Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines. Int J Mol Sci 2017; 18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28914765
  4. Magan-Fernandez A, Fernandez-Barbero JE, F OV et al. Simvastatin exerts antiproliferative and differentiating effects on MG63 osteoblast-like cells: Morphological and immunocytochemical study. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28868611
  5. Villarino N, Signaevskaia L, van Niekerk J et al. A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. Oncotarget 2017; 8:53154-53167. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881801
  6. Kang M, Lee KH, Lee HS et al. Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB/LIN28/let-7 miRNA signaling pathway. PLoS One 2017; 12:e0184644. http://www.ncbi.nlm.nih.gov/pubmed/?term=28910332
  7. Karagkounis G, DeVecchio J, Ferrandon S, Kalady MF. Simvastatin enhances radiation sensitivity of colorectal cancer cells. Surgical endoscopy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916945

CVD

  1. Cariou B, Guerin P, Le May C et al. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study. Diabetes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28865748
  2. Li YH, Wang LH, Li Q et al. Effects of rosuvastatin on pentraxin 3 level and platelet aggregation rate in elderly patients with acute myocardial infarction undergoing elective interventional therapy: a double-blind controlled study. Eur Rev Med Pharmacol Sci 2017; 21:3730-3735. http://www.ncbi.nlm.nih.gov/pubmed/?term=28925467
  3. Wium-Andersen IK, Wium-Andersen MK, Jorgensen MB, Osler M. Anti-inflammatory treatment and risk of depression in 91,842 patients with acute coronary syndrome and 91,860 individuals without acute coronary syndrome in Denmark. Int J Cardiol 2017; 246:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28867006
  4. Nestelberger T, Boeddinghaus J, Badertscher P et al. Effect of Definition on Incidence and Prognosis of Type 2 Myocardial Infarction. J Am Coll Cardiol 2017; 70:1558-1568. http://www.ncbi.nlm.nih.gov/pubmed/?term=28935032
  5. Matsumoto I, Misaki A, Kurozumi M et al. Impact of nonfasting triglycerides/high-density lipoprotein cholesterol ratio on secondary prevention in patients treated with statins. J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916255
  6. Chun KH, Im E, Kim BK et al. Incidence, Predictors, and Clinical Outcomes of New-Onset Diabetes Mellitus after Percutaneous Coronary Intervention with Drug-Eluting Stent. J Korean Med Sci 2017; 32:1603-1609. http://www.ncbi.nlm.nih.gov/pubmed/?term=28875603
  7. Kayikcioglu M. [Cardiovascular prevention and pitavastatin]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:8-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28952472

Ethnicity

  1. Verma AA, Jimenez MP, Subramanian SV et al. Race and Socioeconomic Differences Associated With Changes in Statin Eligibility Under the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28912201
  2. Adua E, Roberts P, Sakyi SA et al. Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study. Clinical and translational medicine 2017; 6:32. http://www.ncbi.nlm.nih.gov/pubmed/?term=28879491
  3. Khan NA, McAlister FA, Pilote L et al. Secondary prevention treatment after acute stroke in older South Asian, Chinese and other Canadians: a retrospective data analysis. CMAJ open 2017; 5:E702-e709. http://www.ncbi.nlm.nih.gov/pubmed/?term=28899946
  4. Lima-Martinez MM, Paoli M, Vazquez-Cardenas A et al. Frequency and clinical and molecular aspects of familial hypercholesterolemia in an endocrinology unit in Ciudad Bolivar, Venezuela. Endocrinologia, diabetes y nutricion 2017; 64:432-439. http://www.ncbi.nlm.nih.gov/pubmed/?term=28895539
  5. Indumathi C, Anusha N, Vinod KV et al. Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils. J Clin Diagn Res 2017; 11:Fc01-fc05. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892923
  6. Chun KH, Im E, Kim BK et al. Incidence, Predictors, and Clinical Outcomes of New-Onset Diabetes Mellitus after Percutaneous Coronary Intervention with Drug-Eluting Stent. J Korean Med Sci 2017; 32:1603-1609. http://www.ncbi.nlm.nih.gov/pubmed/?term=28875603
  7. Soden PA, Zettervall SL, Deery SE et al. Black patients present with more severe vascular disease and a greater burden of risk factors than white patients at time of major vascular intervention. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28951156
  8. Alburikan KA, Nazer RI. Use of the guidelines directed medical therapy after coronary artery bypass graft surgery in Saudi Arabia. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2017; 25:819-822. http://www.ncbi.nlm.nih.gov/pubmed/?term=28951664
  9. Kim J, Lee HS, Nam CM, Heo JH. Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916672

FH

  1. Christensen JJ, Ulven SM, Retterstol K et al. Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study. Atherosclerosis 2017; 266:48-57. http://www.ncbi.nlm.nih.gov/pubmed/?term=28963918
  2. Lima-Martinez MM, Paoli M, Vazquez-Cardenas A et al. Frequency and clinical and molecular aspects of familial hypercholesterolemia in an endocrinology unit in Ciudad Bolivar, Venezuela. Endocrinologia, diabetes y nutricion 2017; 64:432-439. http://www.ncbi.nlm.nih.gov/pubmed/?term=28895539
  3. Polychronopoulos G, Tziomalos K. Novel treatment options for the management of heterozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28884604

Genetics

  1. Bakar NS, Neely D, Avery P et al. Genetic and clinical factors are associated with statin-related myotoxicity of moderate severity: A case-control study. Clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940218
  2. Al-Habsi AA, Massarsky A, Moon TW. Atorvastatin alters gene expression and cholesterol synthesis in primary rainbow trout (Oncorhynchus mykiss) hepatocytes. Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919473
  3. Messas N, Dube MP, Tardif JC. Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies. Curr Atheroscler Rep 2017; 19:43. http://www.ncbi.nlm.nih.gov/pubmed/?term=28944433
  4. Jansen ME, Rigter T, Rodenburg W et al. Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity. Frontiers in pharmacology 2017; 8:555. http://www.ncbi.nlm.nih.gov/pubmed/?term=28878673
  5. Sissung TM, McKeeby JW, Patel J et al. Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. Journal of clinical pharmacology 2017; 57 Suppl 10:S67-s77. http://www.ncbi.nlm.nih.gov/pubmed/?term=28921647

Guidelines

  1. Steicke M, Wang Y. Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. The Annals of pharmacotherapy 2017:1060028017732358. http://www.ncbi.nlm.nih.gov/pubmed/?term=28895424
  2. Waite LH, Phan YL, Spinler SA. Author's Reply to: Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. The Annals of pharmacotherapy 2017:1060028017732359. http://www.ncbi.nlm.nih.gov/pubmed/?term=28922930
  3. White CM, Weeda ER, Nguyen E. Should an LDL-Cholesterol Target-Based Approach Be Readopted? The Annals of pharmacotherapy 2017:1060028017722009. http://www.ncbi.nlm.nih.gov/pubmed/?term=28915766
  4. Verma AA, Jimenez MP, Subramanian SV et al. Race and Socioeconomic Differences Associated With Changes in Statin Eligibility Under the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28912201
  5. Lloyd-Jones DM, Morris PB, Ballantyne CM et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28886926
  6. Lau TW, Tan KE, Choo JC et al. Regional Evidence and International Recommendations to Guide Lipid Management in Asian Patients with Type 2 Diabetes with Special Reference to Renal Dysfunction. Journal of diabetes 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28960806
  7. Grossman DC, Curry SJ, Owens DK. Guideline Recommendations for Statin Therapy. Jama 2017; 318:963-964. http://www.ncbi.nlm.nih.gov/pubmed/?term=28898373
  8. Pagidipati NJ, Navar AM, Pencina MJ. Guideline Recommendations for Statin Therapy-Reply. Jama 2017; 318:964. http://www.ncbi.nlm.nih.gov/pubmed/?term=28898376
  9. Lee DH, Youn HJ, Jung HO et al. Coronary artery calcium score plays an important role for cardiovascular risk stratification in the statin benefit groups of asymptomatic individuals. Lipids Health Dis 2017; 16:172. http://www.ncbi.nlm.nih.gov/pubmed/?term=28899385
  10. Alburikan KA, Nazer RI. Use of the guidelines directed medical therapy after coronary artery bypass graft surgery in Saudi Arabia. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2017; 25:819-822. http://www.ncbi.nlm.nih.gov/pubmed/?term=28951664
  11. Acena A, Martin-Mariscal ML, Tarin N et al. Comparison of 3 Predictive Clinical Risk Scores in 603 Patients with Stable Coronary Artery Disease. Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital 2017; 44:239-244. http://www.ncbi.nlm.nih.gov/pubmed/?term=28878576

LDL- related parameters

  1. Tsujimoto T, Kajio H, Sugiyama T. Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28951019
  2. Koopal C, Marais AD, Westerink J et al. Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized, placebo-controlled, crossover trial. Journal of lipid research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28928170
  3. Sansoy V. [The efficacy and safety of pitavastatin]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:1-4. http://www.ncbi.nlm.nih.gov/pubmed/?term=28952470 

Meta-analyses

  1. White CM, Weeda ER, Nguyen E. Should an LDL-Cholesterol Target-Based Approach Be Readopted? The Annals of pharmacotherapy 2017:1060028017722009. http://www.ncbi.nlm.nih.gov/pubmed/?term=28915766
  2. Islam MM, Yang HC, Nguyen PA et al. Exploring association between statin use and breast cancer risk: an updated meta-analysis. Archives of gynecology and obstetrics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940025
  3. Briasoulis A, Pala M, Telila T et al. Statins and contrast-induced nephropathy: a systematic review and meta-analysis. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28914202
  4. Zhang MZ, Qian DH, Xu JC et al. Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases. J Thorac Dis 2017; 9:2437-2446. http://www.ncbi.nlm.nih.gov/pubmed/?term=28932549
  5. Irwin JC, Khalesi S, Fenning AS, Vella RK. The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: A systematic review and meta-analysis. Pharmacol Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943224

Metabolic Syndrome - Diabetes

  1. Purga SL, Sidhu M, Farkouh M, Schulman-Marcus J. Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28871349
  2. Jung KY, Kim KM, Han SK et al. Effect of Rosuvastatin on Cholesterol Efflux Capacity and Endothelial Function in Type 2 Diabetes Mellitus and Dyslipidemia. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943594
  3. Leiter LA, Cariou B, Muller-Wieland D et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28905478
  4. Li YR, Tsai SS, Lin YS et al. Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction. Diabetology & metabolic syndrome 2017; 9:71. http://www.ncbi.nlm.nih.gov/pubmed/?term=28932290
  5. Giugliano D, Maiorino MI, Bellastella G, Esposito K. Type 2 diabetes and cardiovascular prevention: the dogmas disputed. Endocrine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28895030
  6. Seftel AD. Re: Statin, Testosterone and Phosphodiesterase 5-Inhibitor Treatments and Age Related Mortality in Diabetes. The Journal of urology 2017; 198:727-730. http://www.ncbi.nlm.nih.gov/pubmed/?term=28905759
  7. Beyaz S, Ukinc K. [Pitavastatin and new diabetes development]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:13-15. http://www.ncbi.nlm.nih.gov/pubmed/?term=28952473

New Treatments

  1. Messas N, Dube MP, Tardif JC. Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies. Curr Atheroscler Rep 2017; 19:43. http://www.ncbi.nlm.nih.gov/pubmed/?term=28944433
  2. Nicholls SJ, Puri R. Implications of GLAGOV study. Curr Opin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28937411
  3. Parhofer KG. New approaches to address dyslipidemia. Curr Opin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28902717
  4. Pirillo A, Norata GD, Catapano AL. Strategies for the use of nonstatin therapies. Curr Opin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28914630
  5. Leiter LA, Cariou B, Muller-Wieland D et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28905478
  6. Filippatos TD, Kei A, Elisaf MS. Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? Diseases (Basel, Switzerland) 2017; 5. http://www.ncbi.nlm.nih.gov/pubmed/?term=28961179
  7. Polychronopoulos G, Tziomalos K. Novel treatment options for the management of heterozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28884604
  8. Sabatine MS, Leiter LA, Wiviott SD et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. The lancet. Diabetes & endocrinology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28927706
  9. Wojcik C. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Postgraduate medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28879791

Pleiotropic effects of statins

  1. Gouda A, Helal E, Ali S et al. Maxillary sinus lift using osteoinductive simvastatin combined with beta-TCP versus beta-TCP - a comparative pilot study to evaluate simvastatin enhanced and accelerated bone formation. Acta odontologica Scandinavica 2017:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28952824
  2. Bang UC, Benfield T, Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Alimentary pharmacology & therapeutics 2017; 46:673-680. http://www.ncbi.nlm.nih.gov/pubmed/?term=28880449
  3. Wong JC, Chan HL, Tse YK et al. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. Alimentary pharmacology & therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940673
  4. Kim SM, Ko HK, Noh M et al. Factors Affecting Patency Following Successful Percutaneous Intervention for Dysfunctional Hemodialysis Vascular Access. Annals of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28887254
  5. Marques Dos Santos CH, Dourado DM, Kato da Silva BA et al. Atorvastatin Protect Kidney From Remote Reperfusion Injury. Annals of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28887239
  6. Gao X, Nan Y, Zhao Y et al. Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5. Biochim Biophys Acta 2017; 1862:1512-1519. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919478
  7. Waiyaput W, Pumipichet S, Weerakiet S et al. Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial. BMC women's health 2017; 17:89. http://www.ncbi.nlm.nih.gov/pubmed/?term=28950844
  8. Bhuyan AAM, Nussle S, Cao H et al. Simvastatin, a Novel Stimulator of Eryptosis, the Suicidal Erythrocyte Death. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2017; 43:492-506. http://www.ncbi.nlm.nih.gov/pubmed/?term=28930754
  9. Lee CC, Lee MG, Hsu TC et al. A population-based cohort study on the drug specific effect of statins on sepsis outcome. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28962887
  10. Ma X, Sun D, Li C et al. Statin use and virus-related cirrhosis: A systemic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28866088
  11. Shirinsky IV, Biryukova AA, Shirinsky VS. Simvastatin as an Adjunct to Conventional Therapy of Non-infectious Uveitis: A Randomized, Open-Label Pilot Study. Current eye research 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28937830
  12. Schreiber K, Radin M, Sciascia S. Current insights in obstetric antiphospholipid syndrome. Current opinion in obstetrics & gynecology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28915160
  13. Briasoulis A, Pala M, Telila T et al. Statins and contrast-induced nephropathy: a systematic review and meta-analysis. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28914202
  14. Margaritis M, Sanna F, Antoniades C. Statins and oxidative stress in the cardiovascular system. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28950822
  15. Liu GL, Lei R, Duan SB et al. Atorvastatin alleviates iodinated contrast media-induced cytotoxicity in human proximal renal tubular epithelial cells. Experimental and therapeutic medicine 2017; 14:3309-3313. http://www.ncbi.nlm.nih.gov/pubmed/?term=28912882
  16. Vieira G, Cavalli J, Goncalves ECD et al. Effects of Simvastatin Beyond Dyslipidemia: Exploring Its Antinociceptive Action in an Animal Model of Complex Regional Pain Syndrome-Type I. Frontiers in pharmacology 2017; 8:584. http://www.ncbi.nlm.nih.gov/pubmed/?term=28928655
  17. Kozlowski S, Lipa M, Lipa J, Bomba-Opon D. An experimental administration of pravastatin in patient with previous, multiple pregnancy losses. Ginekologia polska 2017; 88:460-461. http://www.ncbi.nlm.nih.gov/pubmed/?term=28930366
  18. Noronha Oliveira M, Rau LH, Marodin A et al. Ridge Preservation After Maxillary Third Molar Extraction Using 30% Porosity PLGA/HA/beta-TCP Scaffolds With and Without Simvastatin: A Pilot Randomized Controlled Clinical Trial. Implant dentistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28885317
  19. Bleda S, de Haro J, Acin F. Statin potential Nlrp1 inflammasome gene expression modulation via Srebp-1 pathway in peripheral arterial disease. Int J Cardiol 2017; 247:12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916052
  20. Wium-Andersen IK, Wium-Andersen MK, Jorgensen MB, Osler M. Anti-inflammatory treatment and risk of depression in 91,842 patients with acute coronary syndrome and 91,860 individuals without acute coronary syndrome in Denmark. Int J Cardiol 2017; 246:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28867006
  21. Yu SY, Dong B, Tang L, Zhou SH. Statin regulates NLRP1 inflammasome expression through SREBP1: A novel anti-atherosclerotic mechanism. Int J Cardiol 2017; 247:11. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916051
  22. Rajendran S, Kumar KS, Ramesh S, Rao SR. Thermoreversible in situ gel for subgingival delivery of simvastatin for treatment of periodontal disease. International journal of pharmaceutical investigation 2017; 7:101-106. http://www.ncbi.nlm.nih.gov/pubmed/?term=28929053
  23. Swerts AA, Santos BFE, Bruzadelli SR et al. Treatment of experimental periodontal disease by laser therapy in simvastatin-modified rats. Journal of applied oral science : revista FOB 2017; 25:387-395. http://www.ncbi.nlm.nih.gov/pubmed/?term=28877277
  24. Zhang N, Song C, Zhao B et al. Neovascularization and Synaptic Function Regulation with Memantine and Rosuvastatin in a Rat Model of Chronic Cerebral Hypoperfusion. Journal of molecular neuroscience : MN 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28920182
  25. Deck BL, Rick J, Xie SX et al. Statins and Cognition in Parkinson's Disease. Journal of Parkinson's disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28922167
  26. Ambrosio LMB, Rovai ES, Sendyk DI et al. Does the adjunctive use of statins provide additional benefits to nonsurgical periodontal treatment? A systematic review and meta-analysis. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28872188
  27. Zhang MZ, Qian DH, Xu JC et al. Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases. J Thorac Dis 2017; 9:2437-2446. http://www.ncbi.nlm.nih.gov/pubmed/?term=28932549
  28. Freitas Gouveia M, Trueb RM. Unsuccessful Treatment of Alopecia Areata with Simvastatin/Ezetimibe: Experience in 12 Patients. Skin appendage disorders 2017; 3:156-160. http://www.ncbi.nlm.nih.gov/pubmed/?term=28879192
  29. Wan Q, Li L, Yang S, Chu F. Impact of Statins on Arteriovenous Fistulas Outcomes: A Meta-Analysis. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28960860
  30. Janic M, Lunder M, France Stiglic A et al. Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study. Vascul Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28951255

Primary Prevention

  1. Vallejo-Vaz AJ, Robertson M, Catapano AL et al. LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28877913
  2. Orkaby AR, Gaziano JM, Djousse L, Driver JA. Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men. J Am Geriatr Soc 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892121

Registry data

  1. Bang UC, Benfield T, Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Alimentary pharmacology & therapeutics 2017; 46:673-680. http://www.ncbi.nlm.nih.gov/pubmed/?term=28880449
  2. Wong JC, Chan HL, Tse YK et al. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. Alimentary pharmacology & therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940673
  3. Tsujimoto T, Kajio H, Sugiyama T. Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28951019
  4. Lee CC, Lee MG, Hsu TC et al. A population-based cohort study on the drug specific effect of statins on sepsis outcome. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28962887
  5. Miyoshi T, Kohno K, Asonuma H et al. Effect of Intensive and Standard Pitavastatin Treatment With or Without Eicosapentaenoic Acid on Progression of Coronary Artery Calcification Over 12 Months- Prospective Multicenter Study. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28867681
  6. Adua E, Roberts P, Sakyi SA et al. Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study. Clinical and translational medicine 2017; 6:32. http://www.ncbi.nlm.nih.gov/pubmed/?term=28879491
  7. Bartlett LE, Pratt N, Roughead EE. Does a fixed dose combination of amlodipine and atorvastatin improve persistence to therapy in the Australian population? Current medical research and opinion 2017:1-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28945105
  8. Cariou B, Guerin P, Le May C et al. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study. Diabetes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28865748
  9. Corrao G, Monzio Compagnoni M, Rea F et al. Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort. Diabetes Res Clin Pract 2017; 133:60-68. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892732
  10. Wium-Andersen IK, Wium-Andersen MK, Jorgensen MB, Osler M. Anti-inflammatory treatment and risk of depression in 91,842 patients with acute coronary syndrome and 91,860 individuals without acute coronary syndrome in Denmark. Int J Cardiol 2017; 246:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28867006
  11. Orkaby AR, Gaziano JM, Djousse L, Driver JA. Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men. J Am Geriatr Soc 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892121
  12. Matsumoto I, Misaki A, Kurozumi M et al. Impact of nonfasting triglycerides/high-density lipoprotein cholesterol ratio on secondary prevention in patients treated with statins. J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916255
  13. Indumathi C, Anusha N, Vinod KV et al. Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils. J Clin Diagn Res 2017; 11:Fc01-fc05. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892923
  14. Deck BL, Rick J, Xie SX et al. Statins and Cognition in Parkinson's Disease. Journal of Parkinson's disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28922167
  15. Carmo M, Barbetta I, Bissacco D et al. Development and validation of a score to predict life expectancy after carotid endarterectomy in asymptomatic patients. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943008
  16. Lee DH, Youn HJ, Jung HO et al. Coronary artery calcium score plays an important role for cardiovascular risk stratification in the statin benefit groups of asymptomatic individuals. Lipids Health Dis 2017; 16:172. http://www.ncbi.nlm.nih.gov/pubmed/?term=28899385
  17. Tvaryanas AP, Wagner JH, Maupin GM, Schroeder VM. Statins and Musculoskeletal Conditions in U.S. Air Force Active Duty Service Members. Military medicine 2017; 182:e1938-e1945. http://www.ncbi.nlm.nih.gov/pubmed/?term=28885959
  18. Tanskanen A, Taipale H, Koponen M et al. Drug exposure in register-based research-An expert-opinion based evaluation of methods. PLoS One 2017; 12:e0184070. http://www.ncbi.nlm.nih.gov/pubmed/?term=28886089
  19. Alburikan KA, Nazer RI. Use of the guidelines directed medical therapy after coronary artery bypass graft surgery in Saudi Arabia. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2017; 25:819-822. http://www.ncbi.nlm.nih.gov/pubmed/?term=28951664
  20. Siriangkhawut M, Tansakul P, Uchaipichat V. Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2017; 25:823-829. http://www.ncbi.nlm.nih.gov/pubmed/?term=28951665
  21. Kim J, Lee HS, Nam CM, Heo JH. Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916672
  22. Wan Q, Li L, Yang S, Chu F. Impact of Statins on Arteriovenous Fistulas Outcomes: A Meta-Analysis. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28960860

Renal Disease

  1. Al Hamarneh YN, Tsuyuki RT, Jones CA et al. Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled RxEACH Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28912054
  2. Li YR, Tsai SS, Lin YS et al. Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction. Diabetology & metabolic syndrome 2017; 9:71. http://www.ncbi.nlm.nih.gov/pubmed/?term=28932290
  3. Takahashi EA, Kallmes DF, Fleming CJ et al. Predictors and Outcomes of Postcontrast Acute Kidney Injury after Endovascular Renal Artery Intervention. Journal of vascular and interventional radiology : JVIR 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28947366
  4. Kanno M, Nakayama M, Zhu WJ et al. Rosuvastatin pretreatment suppresses distant organ injury following unilateral renal ischemia-reperfusion in hypertensive Dahl salt-sensitive rats. Nephrology (Carlton) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940950

Reviews

  1. Zhou Z, Albarqouni L, Breslin M et al. Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017; 7:e017587. http://www.ncbi.nlm.nih.gov/pubmed/?term=28963307
  2. Purga SL, Sidhu M, Farkouh M, Schulman-Marcus J. Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28871349
  3. Ma X, Sun D, Li C et al. Statin use and virus-related cirrhosis: A systemic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28866088
  4. Messas N, Dube MP, Tardif JC. Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies. Curr Atheroscler Rep 2017; 19:43. http://www.ncbi.nlm.nih.gov/pubmed/?term=28944433
  5. Margaritis M, Sanna F, Antoniades C. Statins and oxidative stress in the cardiovascular system. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28950822
  6. Joo MK, Park JJ, Chun HJ. Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors. Dig Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881340
  7. Filippatos TD, Kei A, Elisaf MS. Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? Diseases (Basel, Switzerland) 2017; 5. http://www.ncbi.nlm.nih.gov/pubmed/?term=28961179
  8. Giugliano D, Maiorino MI, Bellastella G, Esposito K. Type 2 diabetes and cardiovascular prevention: the dogmas disputed. Endocrine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28895030
  9. Polychronopoulos G, Tziomalos K. Novel treatment options for the management of heterozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28884604
  10. Jansen ME, Rigter T, Rodenburg W et al. Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity. Frontiers in pharmacology 2017; 8:555. http://www.ncbi.nlm.nih.gov/pubmed/?term=28878673
  11. Hong JY, Kim HS, Choi IY. Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity. Healthcare informatics research 2017; 23:199-207. http://www.ncbi.nlm.nih.gov/pubmed/?term=28875055
  12. Lin XL, Liu MH. Statin and ezetimibe combination therapy: New therapeutic options for lowering Low-Density Lipoprotein Cholesterol. Int J Cardiol 2017; 247:49. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916087
  13. Sissung TM, McKeeby JW, Patel J et al. Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. Journal of clinical pharmacology 2017; 57 Suppl 10:S67-s77. http://www.ncbi.nlm.nih.gov/pubmed/?term=28921647
  14. Lau TW, Tan KE, Choo JC et al. Regional Evidence and International Recommendations to Guide Lipid Management in Asian Patients with Type 2 Diabetes with Special Reference to Renal Dysfunction. Journal of diabetes 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28960806
  15. Ambrosio LMB, Rovai ES, Sendyk DI et al. Does the adjunctive use of statins provide additional benefits to nonsurgical periodontal treatment? A systematic review and meta-analysis. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28872188
  16. Wojcik C. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Postgraduate medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28879791
  17. Acena A, Martin-Mariscal ML, Tarin N et al. Comparison of 3 Predictive Clinical Risk Scores in 603 Patients with Stable Coronary Artery Disease. Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital 2017; 44:239-244. http://www.ncbi.nlm.nih.gov/pubmed/?term=28878576
  18. Beyaz S, Ukinc K. [Pitavastatin and new diabetes development]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:13-15. http://www.ncbi.nlm.nih.gov/pubmed/?term=28952473
  19. Kayikcioglu M. [Cardiovascular prevention and pitavastatin]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:8-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28952472
  20. Sansoy V. [The efficacy and safety of pitavastatin]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:1-4. http://www.ncbi.nlm.nih.gov/pubmed/?term=28952470
  21. Tokgozoglu L. [Efficacy of pitavastatin on HDL-cholesterol]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:5-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28952471

Safety and side effects

  1. Ayubi E, Safiri S. Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin; Methodologic Issues. Am J Med 2017; 130:e467. http://www.ncbi.nlm.nih.gov/pubmed/?term=28927545
  2. Simakova MN, Bisen S, Dopico AM, Bukiya AN. Statin therapy exacerbates alcohol-induced constriction of cerebral arteries via modulation of ethanol-induced BK channel inhibition in vascular smooth muscle. Biochem Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28865873
  3. Zhou Z, Albarqouni L, Breslin M et al. Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017; 7:e017587. http://www.ncbi.nlm.nih.gov/pubmed/?term=28963307
  4. Bakar NS, Neely D, Avery P et al. Genetic and clinical factors are associated with statin-related myotoxicity of moderate severity: A case-control study. Clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940218
  5. Waters MJ, Limaye V. Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort. Clinical rheumatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28905130
  6. Corrao G, Monzio Compagnoni M, Rea F et al. Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort. Diabetes Res Clin Pract 2017; 133:60-68. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892732
  7. Anand K, Sketris I, Zhang Y et al. The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin. Drugs - real world outcomes 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28956294
  8. van Diemen MPJ, Berends CL, Akram N et al. Validation of a pharmacological model for mitochondrial dysfunction in healthy subjects using simvastatin: A randomized placebo-controlled proof-of-pharmacology study. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943100
  9. Leite GAA, Figueiredo TM, Pacheco TL et al. Vitamin C partially prevents reproductive damage in adult male rats exposed to rosuvastatin during prepuberty. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28887090
  10. Jansen ME, Rigter T, Rodenburg W et al. Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity. Frontiers in pharmacology 2017; 8:555. http://www.ncbi.nlm.nih.gov/pubmed/?term=28878673
  11. Hong JY, Kim HS, Choi IY. Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity. Healthcare informatics research 2017; 23:199-207. http://www.ncbi.nlm.nih.gov/pubmed/?term=28875055
  12. Tse DY, Kim SJ, Chung I et al. The ocular toxicity and pharmacokinetics of simvastatin following intravitreal injection in mice. International journal of ophthalmology 2017; 10:1361-1369. http://www.ncbi.nlm.nih.gov/pubmed/?term=28944193
  13. Taylor BA, Sanchez RJ, Jacobson TA et al. Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy. J Am Coll Cardiol 2017; 70:1680-1681. http://www.ncbi.nlm.nih.gov/pubmed/?term=28935043
  14. Indumathi C, Anusha N, Vinod KV et al. Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils. J Clin Diagn Res 2017; 11:Fc01-fc05. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892923
  15. Chun KH, Im E, Kim BK et al. Incidence, Predictors, and Clinical Outcomes of New-Onset Diabetes Mellitus after Percutaneous Coronary Intervention with Drug-Eluting Stent. J Korean Med Sci 2017; 32:1603-1609. http://www.ncbi.nlm.nih.gov/pubmed/?term=28875603
  16. Seftel AD. Re: Statin, Testosterone and Phosphodiesterase 5-Inhibitor Treatments and Age Related Mortality in Diabetes. The Journal of urology 2017; 198:727-730. http://www.ncbi.nlm.nih.gov/pubmed/?term=28905759
  17. Takahashi EA, Kallmes DF, Fleming CJ et al. Predictors and Outcomes of Postcontrast Acute Kidney Injury after Endovascular Renal Artery Intervention. Journal of vascular and interventional radiology : JVIR 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28947366
  18. Carris NW, Tipparaju SM, Magness DJ et al. Pleiotropic effects of metformin to rescue statin-induced muscle injury and insulin resistance: A proposed mechanism and potential clinical implications. Medical hypotheses 2017; 107:39-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=28915960
  19. Tvaryanas AP, Wagner JH, Maupin GM, Schroeder VM. Statins and Musculoskeletal Conditions in U.S. Air Force Active Duty Service Members. Military medicine 2017; 182:e1938-e1945. http://www.ncbi.nlm.nih.gov/pubmed/?term=28885959
  20. Irwin JC, Khalesi S, Fenning AS, Vella RK. The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: A systematic review and meta-analysis. Pharmacol Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943224
  21. Siriangkhawut M, Tansakul P, Uchaipichat V. Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2017; 25:823-829. http://www.ncbi.nlm.nih.gov/pubmed/?term=28951665
  22. Urbano F, Bugliani M, Filippello A et al. Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat beta-Cells. Direct Effect of Oxidative Stress. Scientific reports 2017; 7:11863. http://www.ncbi.nlm.nih.gov/pubmed/?term=28928397
  23. Atilano-Roque A, Joy MS. Characterization of simvastatin acid uptake by organic anion transporting polypeptide 3A1 (OATP3A1) and influence of drug-drug interaction. Toxicology in vitro : an international journal published in association with BIBRA 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28887287
  24. Cherkas Y, McMillian MK, Amaratunga D et al. ABC gene-ranking for prediction of drug-induced cholestasis in rats. Toxicology reports 2016; 3:252-261. http://www.ncbi.nlm.nih.gov/pubmed/?term=28959545
  25. Elena C, Cristina C, Salvatore T et al. A severe myopathy case in aged patient treated with high statin dosage. Toxicology reports 2017; 4:438-440. http://www.ncbi.nlm.nih.gov/pubmed/?term=28959671

Stroke and CNS

  1. Bravata DM, Myers LJ, Cheng E et al. Development and Validation of Electronic Quality Measures to Assess Care for Patients With Transient Ischemic Attack and Minor Ischemic Stroke. Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28912200
  2. Khan NA, McAlister FA, Pilote L et al. Secondary prevention treatment after acute stroke in older South Asian, Chinese and other Canadians: a retrospective data analysis. CMAJ open 2017; 5:E702-e709. http://www.ncbi.nlm.nih.gov/pubmed/?term=28899946
  3. Zhong P, Wu D, Ye X et al. Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis. Drug design, development and therapy 2017; 11:2517-2526. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919704
  4. Hosomi N, Nagai Y, Kitagawa K et al. Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28924103
  5. Zhang N, Song C, Zhao B et al. Neovascularization and Synaptic Function Regulation with Memantine and Rosuvastatin in a Rat Model of Chronic Cerebral Hypoperfusion. Journal of molecular neuroscience : MN 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28920182
  6. Guirao V, Marti-Sistac O, DeGregorio-Rocasolano N et al. Specific rescue by ortho-hydroxy atorvastatin of cortical GABAergic neurons from previous oxygen/glucose deprivation: role of pCREB. Journal of neurochemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881028
  7. Deck BL, Rick J, Xie SX et al. Statins and Cognition in Parkinson's Disease. Journal of Parkinson's disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28922167
  8. Carmo M, Barbetta I, Bissacco D et al. Development and validation of a score to predict life expectancy after carotid endarterectomy in asymptomatic patients. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943008
  9. Kim J, Lee HS, Nam CM, Heo JH. Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916672

Triglycerides/HDL

  1. Honda S, Sidharta SL, Shishikura D et al. High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy. Atherosclerosis 2017; 265:110-116. http://www.ncbi.nlm.nih.gov/pubmed/?term=28881268
  2. Jung KY, Kim KM, Han SK et al. Effect of Rosuvastatin on Cholesterol Efflux Capacity and Endothelial Function in Type 2 Diabetes Mellitus and Dyslipidemia. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943594
  3. Matsumoto I, Misaki A, Kurozumi M et al. Impact of nonfasting triglycerides/high-density lipoprotein cholesterol ratio on secondary prevention in patients treated with statins. J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28916255
  4. Koopal C, Marais AD, Westerink J et al. Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized, placebo-controlled, crossover trial. Journal of lipid research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28928170
  5. Tokgozoglu L. [Efficacy of pitavastatin on HDL-cholesterol]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:5-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28952471

Trials

  1. Gouda A, Helal E, Ali S et al. Maxillary sinus lift using osteoinductive simvastatin combined with beta-TCP versus beta-TCP - a comparative pilot study to evaluate simvastatin enhanced and accelerated bone formation. Acta odontologica Scandinavica 2017:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28952824
  2. Al Hamarneh YN, Tsuyuki RT, Jones CA et al. Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled RxEACH Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28912054
  3. Christensen JJ, Ulven SM, Retterstol K et al. Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study. Atherosclerosis 2017; 266:48-57. http://www.ncbi.nlm.nih.gov/pubmed/?term=28963918
  4. Pokharel Y, Sharma PP, Qintar M et al. High-sensitivity C-reactive protein levels and health status outcomes after myocardial infarction. Atherosclerosis 2017; 266:16-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=28946036
  5. Waiyaput W, Pumipichet S, Weerakiet S et al. Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial. BMC women's health 2017; 17:89. http://www.ncbi.nlm.nih.gov/pubmed/?term=28950844
  6. Guimaraes ES, Cerda A, Dorea EL et al. Effects of short term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940978
  7. Jung KY, Kim KM, Han SK et al. Effect of Rosuvastatin on Cholesterol Efflux Capacity and Endothelial Function in Type 2 Diabetes Mellitus and Dyslipidemia. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943594
  8. Vallejo-Vaz AJ, Robertson M, Catapano AL et al. LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28877913
  9. Bakar NS, Neely D, Avery P et al. Genetic and clinical factors are associated with statin-related myotoxicity of moderate severity: A case-control study. Clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28940218
  10. Shirinsky IV, Biryukova AA, Shirinsky VS. Simvastatin as an Adjunct to Conventional Therapy of Non-infectious Uveitis: A Randomized, Open-Label Pilot Study. Current eye research 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28937830
  11. Nicholls SJ, Puri R. Implications of GLAGOV study. Curr Opin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28937411
  12. Li YR, Tsai SS, Lin YS et al. Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction. Diabetology & metabolic syndrome 2017; 9:71. http://www.ncbi.nlm.nih.gov/pubmed/?term=28932290
  13. Zhong P, Wu D, Ye X et al. Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis. Drug design, development and therapy 2017; 11:2517-2526. http://www.ncbi.nlm.nih.gov/pubmed/?term=28919704
  14. van Diemen MPJ, Berends CL, Akram N et al. Validation of a pharmacological model for mitochondrial dysfunction in healthy subjects using simvastatin: A randomized placebo-controlled proof-of-pharmacology study. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28943100
  15. Li YH, Wang LH, Li Q et al. Effects of rosuvastatin on pentraxin 3 level and platelet aggregation rate in elderly patients with acute myocardial infarction undergoing elective interventional therapy: a double-blind controlled study. Eur Rev Med Pharmacol Sci 2017; 21:3730-3735. http://www.ncbi.nlm.nih.gov/pubmed/?term=28925467
  16. Noronha Oliveira M, Rau LH, Marodin A et al. Ridge Preservation After Maxillary Third Molar Extraction Using 30% Porosity PLGA/HA/beta-TCP Scaffolds With and Without Simvastatin: A Pilot Randomized Controlled Clinical Trial. Implant dentistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28885317
  17. Nestelberger T, Boeddinghaus J, Badertscher P et al. Effect of Definition on Incidence and Prognosis of Type 2 Myocardial Infarction. J Am Coll Cardiol 2017; 70:1558-1568. http://www.ncbi.nlm.nih.gov/pubmed/?term=28935032
  18. Hosomi N, Nagai Y, Kitagawa K et al. Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28924103
  19. Koopal C, Marais AD, Westerink J et al. Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized, placebo-controlled, crossover trial. Journal of lipid research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28928170
  20. Nishiguchi T, Kubo T, Tanimoto T et al. Effect of Early Pitavastatin Therapy on Coronary Fibrous-Cap Thickness Assessed by Optical Coherence Tomography in Patients With Acute Coronary Syndrome: The ESCORT Study. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28917689
  21. Sabatine MS, Leiter LA, Wiviott SD et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. The lancet. Diabetes & endocrinology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28927706
  22. Freitas Gouveia M, Trueb RM. Unsuccessful Treatment of Alopecia Areata with Simvastatin/Ezetimibe: Experience in 12 Patients. Skin appendage disorders 2017; 3:156-160. http://www.ncbi.nlm.nih.gov/pubmed/?term=28879192

Women and elderly

  1. Waiyaput W, Pumipichet S, Weerakiet S et al. Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial. BMC women's health 2017; 17:89. http://www.ncbi.nlm.nih.gov/pubmed/?term=28950844
  2. Schreiber K, Radin M, Sciascia S. Current insights in obstetric antiphospholipid syndrome. Current opinion in obstetrics & gynecology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28915160
  3. Li YH, Wang LH, Li Q et al. Effects of rosuvastatin on pentraxin 3 level and platelet aggregation rate in elderly patients with acute myocardial infarction undergoing elective interventional therapy: a double-blind controlled study. Eur Rev Med Pharmacol Sci 2017; 21:3730-3735. http://www.ncbi.nlm.nih.gov/pubmed/?term=28925467
  4. Orkaby AR, Gaziano JM, Djousse L, Driver JA. Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men. J Am Geriatr Soc 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28892121
  5. Ofori-Asenso R, Jakhu A, Zomer E et al. Adherence and Persistence among Statin Users aged 65 years and over: A Systematic Review and Meta-analysis. J Gerontol A Biol Sci Med Sci 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28958039

 


Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.